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Dual-specificity tyrosine-(Y)-phosphorylation-regu-
lated kinases (DYRKs) play key roles in brain devel-
opment, regulation of splicing, and apoptosis, and
are potential drug targets for neurodegenerative dis-
eases and cancer. We present crystal structures of
one representativemember of each DYRK subfamily:
DYRK1A with an ATP-mimetic inhibitor and
consensus peptide, and DYRK2 including NAPA
and DH (DYRK homology) box regions. The current
activation model suggests that DYRKs are Ser/Thr
kinases that only autophosphorylate the second
tyrosine of the activation loop YxY motif during pro-
tein translation. The structures explain the roles of
this tyrosine and of the DH box in DYRK activation
and provide a structural model for DYRK substrate
recognition. Phosphorylation of a library of naturally
occurring peptides identified substrate motifs that
lack proline in the P+1 position, suggesting that
DYRK1A is not a strictly proline-directed kinase.
Our data also show that DYRK1A wild-type and
Y321F mutant retain tyrosine autophosphorylation
activity.
INTRODUCTION
The dual-specificity tyrosine-phosphorylation-regulated kinases
(DYRKs) are an evolutionarily conserved family of kinases with
five human members (DYRK1A, DYRK1B, DYRK2, DYRK3,
and DYRK4). They belong to the CMGC family of serine/threo-
nine (S/T) kinases and are categorized as class I (DYRK1A and
DYRK1B) and class II (DYRK2, DYRK3, and DYRK4) DYRKs.986 Structure 21, 986–996, June 4, 2013 ª2013 Elsevier Ltd All rightsThe best-studied member of the DYRK family is DYRK1A, owing
to its role in the pathology of Down syndrome and the early onset
of neurodegeneration. DYRKmembers have been clearly shown
to participate in important signaling pathways that control post-
embryonic neurogenesis, developmental processes, cell sur-
vival, differentiation, and death (Arron et al., 2006; Mercer
et al., 2005; Tejedor et al., 1995). In addition, recent studies
show DYRK1A and DYRK2 phosphorylate NFATc, countering
the effect of calcium signaling and maintaining inactive NFATc
(Arron et al., 2006; Gwack et al., 2006; Lee et al., 2009).
The first evidence for the key role of DYRK1A in neural prolif-
eration and neurogenesis of the developing brain was provided
by mutational analysis of the DYRK Drosophila ortholog mini-
brain (mnb), where loss-of-function mutations resulted in
reduced brain size (Tejedor et al., 1995). DYRK1A is localized
in the Down syndrome (DS) critical region of chromosome 21
that has been linked to the development of DS phenotypes
when triplicated (Delabar et al., 1993; Sinet et al., 1994). Indeed,
triplication of the DYRK1A locus in DS results in overexpression
of DYRK1A in the fetal as well as adult brain and strongly impli-
cates DYRK1A in neurodevelopmental alterations linked to some
DS pathologies and disease predispositions (Dowjat et al.,
2007). These links prompted studies on the role of DYRK1A in
age-associated neurodegeneration and suggested DYRK1A as
a target for the development of inhibitors (Mazur-Kolecka
et al., 2012; Park et al., 2009). The bindingmodes of the inhibitors
INDY and Harmine in DYRK1A have recently been published
(Ogawa et al., 2010).
Apart from the well-studied DYRK1A isozyme, studies have
provided evidence for the roles of DYRK1B in the development
of various sarcomas (Deng et al., 2006) and in skeletal muscle
differentiation (Deng et al., 2003, 2005). DYRK2 is reported to
regulate key developmental and cellular processes such as neu-
rogenesis, cell proliferation, cytokinesis, and cellular differentia-
tion (Taira et al., 2007; Woods et al., 2001; Yoshida, 2008).
Notably, DYRK2 may function in DNA damage signalingreserved
Figure 1. Domain Arrangement of Human DYRK Family Kinases
The construct boundaries for the crystallized DYRK1A andDYRK2 proteins are
indicated. NLS, nuclear localization signal; PEST, PEST domain. See also
Figure S1.
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Activation and Substrate Recognition of DYRKspathways, because it phosphorylates p53 at Ser46 in response
to DNA damage, which induces cellular apoptosis after geno-
toxic stress (Taira et al., 2007). In addition, ataxia telangiectasia
mutated was shown to phosphorylate nuclear DYRK2 upon DNA
damage, which appeared to enable DYRK2 to protect itself from
degradation that occurs due to its association with MDM2 under
normal conditions (Taira et al., 2010). Emerging studies show
DYRK2 has important roles in protein proteolysis, proteosomal
degradation, and tumor progression (Varjosalo et al., 2008;
Maddika and Chen, 2009; Taira et al., 2012). As for
DYRK3 and DYRK4, their physiological functions remain poorly
understood.
All DYRKs contain a conserved catalytic kinase domain pre-
ceded by the DYRK-characteristic DYRK homology (DH) box
(Figure 1A; for a sequence alignment, see Figure S1 available on-
line). DYRKs rapidly autoactivate during folding by phosphoryla-
tion on the second tyrosine residue of the conserved activation
loop YxY motif (Tyr321 of DYRK1A). This tyrosine corresponds
to the secondary activation loop phosphorylation site in the
TxY motif in MAPKs. It was reported based on studies with
Drosophila melanogaster DYRKs that this phosphorylation event
occurs in ciswhile DYRK is still bound to the ribosome, and sub-
sequently DYRKs lose tyrosine phosphorylation ability and retain
only S/T phosphorylation ability (Lochhead et al., 2005). For the
human DYRK1A, mutation of Tyr321 or dephosphorylation did
not abolish kinase activity (Adayev et al., 2007).
DYRKs were initially assumed to be proline-directed S/T
kinases with specificity for proline and arginine at P+1 and
P3 positions, respectively (Himpel et al., 2000). However,
further investigations revealed DYRK cellular substrates (e.g.,
synuclein; Kim et al., 2006) with a wide variation in phosphoryla-
tion motifs (Aranda et al., 2011).
To understand the molecular mechanism of DYRK1A activa-
tion, the roles of Tyr321 phosphorylation and regulatory ele-
ments located N-terminal to the catalytic domain, as well as
substrate recognition, we determined the structure of the phos-
phorylated DYRK1A and DYRK2 catalytic domain and N-termi-
nal regulatory DH box sections. The autophosphorylation
behavior of DYRK1A was analyzed, and the substrate specificity
of DYRK1A, DYRK1B, and DYRK2 was investigated using a
novel mass spectrometry methodology (Kettenbach et al.,
2012). The structure of a ternary substrate complex of DYRK1A,
the ATP-mimetic inhibitor DJM2005, and a consensus substrate
peptide (RARPGT*PALRE) reveals how DYRK1A recognizesStructure 21substrates and provides a model for the structure-based design
of selective DYRK inhibitors.
RESULTS
Structures of the DYRK1A and DYRK2 Catalytic Domain
and DH Box
The crystal structures of DYRK1A and DYRK2 comprising the
catalytic kinase domain and DH box were determined. The
DYRK1A structure was determined from a construct expressing
residues 127–485 of human DYRK1A (National Center for
Biotechnology Information [NCBI] genInfo identifier [gi] number
18765758). Residues Val135–Lys480 comprising the DH box
and kinase domain were resolved in the electron density. The
structure was determined in complex with the ATP-competitive
inhibitor (S)-N-(5-(4-amino-2-(3-chlorophenyl)butanamido)-1H-
indazol-3-yl)benzamide (DJM2005) at 2.40 A˚ resolution (Fig-
ure 2A; Table 1). The inhibitor DJM2005 was kindly provided
by the laboratory of Kevan Shokat; the chemical structure is
shown in Figure S2.
The DYRK2 structure was determined from a construct ex-
pressing residues 74–479 of human DYRK2 (NCBI gi number
4503427). Residues Gly74–Pro470 comprising NAPA1 (N-termi-
nal autophosphorylation accessory 1), NAPA2, DH box, and
kinase domain were resolved in the electron density, as well as
part of the N-terminal purification tag. The structure was deter-
mined in the absence of inhibitor (apo form) at 2.36 A˚ resolution
(Figure 2B; Table 1).
For both DYRK1A and DYRK2 the entire catalytic domain was
well ordered, including a long hairpin-like structure for the N-ter-
minal DH box and an active kinase conformation with a fully or-
dered activation segment (Figure 2). Mass spectrometry showed
that the purified DYRKs were heterogeneously phosphorylated
in solution (data not shown). However, the electron density
maps only showed clear evidence of phosphorylation of
DYRK1A at the second tyrosine of the dual-phosphorylation
motif YxY (Tyr321) and double phosphorylation of DYRK2 at
Ser159 of the glycine-rich loop and Tyr309 of the activation
loop. The other phosphorylation sites might either have had
low occupancy or were located in unstructured regions of the
protein.
The DYRK1A and DYRK2 structures superimpose with a
root-mean-square deviation (rmsd) of 1.03 A˚ over 297 Ca atoms
(using chain A of the DYRK1A structure). In DYRK1A, the ATP-
mimetic inhibitor DJM2005 binds to the ATP binding site, form-
ing three hydrogen bonds with the hinge backbone and an
additional two hydrogen bonds from the inhibitor’s primary
amine with the side chains of Asn292 and the DFG motif aspar-
tate Asp307 (Figure 2C). There is also an electrostatic interac-
tion via an ion (modeled as chloride) linking an inhibitor amide
nitrogen to the backbone nitrogen of Asp307 from the DFG
motif, and hydrogen bonding via a water molecule to the back-
bone carbonyl of Glu291. There are various favorable hydropho-
bic interactions with DYRK1A active site residues, including at
the entrance to the ATP site, where the side chain of Tyr243
packs against the inhibitor’s phenyl ring. All of the DYRK1A res-
idues involved in hydrogen bonding to the inhibitor are
conserved in DYRK2 (Figure S3); there are, however, some po-
tential differences in the hydrophobic interactions, such as the, 986–996, June 4, 2013 ª2013 Elsevier Ltd All rights reserved 987
Figure 2. Structures of DYRK1A and DYRK2
(A) Structure of DYRK1A kinase domain and DYRK
homology box with the inhibitor DJM2005 bound in
the ATP binding site. The DH box and CMGC-spe-
cific inset are shown in magenta and the activation
segment in orange.
(B) Similar view of DYRK2 showing the NAPA region
and DH box in magenta.
(C) Active site of DYRK1A with inhibitor DJM2005
bound. Part of strand b1 has been removed for
clarity. The inhibitor is colored yellow, the protein is
colored as in (A), and hydrogen bonds are shown as
dashed red lines.
See also Figure S3.
(D) Correlation of the binding of various kinase in-
hibitors (measured by DTm) to DYRK1A and DYRK2
showing that whereas some inhibitors bind both
proteins, the active site differences allow for
DYRK1A- or DYRK2-specific inhibitors.
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Activation and Substrate Recognition of DYRKsreplacement of Tyr243 with Met233 in DYRK2 as well as differ-
ences at the back of the pocket and the hydrophobic residue
preceding the DFG motif. Analysis of changes in DYRK1A and
DYRK2 temperature shift values (DTm) in the presence of a set
of potential kinase inhibitors showed only weak correlation,
and therefore that it is possible to have DYRK1A- or DYRK2-
specific inhibitors, as shown by some of the inhibitors screened
that give changes in Tm with only DYRK1A or only DYRK2
(Figure 2D).
Interestingly, the inhibitor’s primary amine also interacts with a
sulfate molecule from the DYRK1A crystallization buffer that is
found in a similar location as an autophosphorylated serine res-
idue in DYRK2 (pS159; Figure S3). This sulfate is also bound by
the side chains of Asp307 of the DFG motif, Ser169 of the
glycine-rich loop, and Lys289 of the catalytic loop, and is in a
similar position as that of a hydrolyzed g-phosphate from ATP
bound to PKA (Protein Data Bank [PDB] ID code 1RDQ; Yang
et al., 2004) or a bound phosphate in the structure of Haspin
with a 5-iodotubercidin ligand (PDB ID code 3IQ7; Eswaran
et al., 2009). Addition of negatively charged groups to inhibitors
to exploit this conserved binding pocket may help inhibitor
design for some of these kinases.
The C-terminal lobe reveals several unique features that
define the DYRK family. The MAP kinase characteristic inser-
tion observed in the C lobe of DYRKs (Figure 2) is extended988 Structure 21, 986–996, June 4, 2013 ª2013 Elsevier Ltd All rights reservedin comparison with other CMGC family
members such as CLK1, CLK3 (Bullock
et al., 2009), GSK3b (Dajani et al., 2001),
or MAPKs (Canagarajah et al., 1997). In
DYRK1A, this insert forms an elaborate
subdomain of 40 residues comprising
two short helices followed by an antipar-
allel b sheet that is conserved in vertebrate
DYRK1 family members but not in
Drosophila mnb. In DYRK2, this insert
also forms a distinctive subdomain with
two short helices and three short antipar-
allel b sheets. Along with the structural
divergence between DYRK1A and DYRK2in this insertion, this region is also the place of greatest diver-
gence among the other DYRK family members.
Regulatory Role of the N-Terminal Region
Deletion of the entire region of DYRK1A N-terminal to the kinase
domain (1–148) has been shown to decrease catalytic activity
(Himpel et al., 2001). In Drosophila, the DH box was required
for phosphorylation of SNR1 by DYRK2 but not by DYRK1 (Kin-
strie et al., 2006). With Drosophila DYRKs, the NAPA regions are
required for the transient intramolecular tyrosine kinase activity
of DYRKs (Kinstrie et al., 2010) and are conserved across a
wide range of eukaryotes, including for Trypanosoma brucei
DYRK2, where the NAPA1 and NAPA2 regions are required for
tyrosine autophosphorylation (Han et al., 2012). In the following
analysis, the DH boxes and NAPA regions are those defined by
Kinstrie et al. (2010).
In both DYRK1A and DYRK2, the N-terminal region containing
the DH box is positioned on top of the N-terminal lobe of the
kinase domain and forms a large network of interactions with
all five strands of the N lobe b sheet, providing considerable sta-
bilization (Figures 3A and 3B). The most highly conserved resi-
dues in the DH box are those essential for stabilization of its
folded state, in particular the two central tyrosines, Tyr140 and
Tyr147, in DYRK1A (Figure 3A). This compact folded DH box
appears essential for the formation of tertiary structure in the
Table 1. Data Collection and Refinement Statistics
DYRK1A-Inhibitora DYRK1A-Inhibitora-Peptide DYRK2
PDB ID code 2VX3 2WO6 3K2L
Crystallization conditions 4% (v/v) PEG 300, 0.1 M Li2SO4,
0.1 M Tris, pH 8.5
0.2 M sodium formate, 20% (w/v)
PEG 3350, 10% ethylene glycol
1.26 M (NH4)2SO4, 0.2 M Li2SO4,
0.1 M Tris, pH 8.5
Space group C2 P65 P42212




a, b, c (A˚) 264.2, 65.1, 140.3 168.4, 168.4, 62.4 84.3, 84.3, 148.5
a, b, g () 90.0, 115.44, 90.0 90.0, 90.0, 120.0 90.0, 90.0, 90.0
Data Collection
Beamline SLS X10SA Diamond I02 Diamond I03
Resolution range (A˚)b 27.24–2.40 (2.53–2.40) 55.13–2.50 (2.64–2.50) 42.19–2.36 (2.49–2.36)
Unique observationsb 85,770 (12,458) 35,283 (5,093) 22,801 (3,275)
Average multiplicityb 3.4 (3.2) 7.5 (6.9) 6.2 (6.4)
Completeness (%)b 99.9 (99.9) 100.0 (100.0) 99.8 (100.0)
Rmerge
b 0.10 (0.82) 0.18 (0.57) 0.08 (0.90)
Mean (I)/s(I)b 9.5 (1.9) 10.8 (3.7) 12.2 (2.1)
Refinement
Resolution range (A˚) 26.00–2.40 40.00–2.50 42.19–2.36
R value, Rfree 0.19, 0.23 0.19, 0.23 0.23, 0.29
Mean protein B values (A˚2) 53 23.1c 33.8c
Mean ligand B values (A˚2) 46 (inhibitor) 34 (inhibitor)
71 (peptide)
Rmsd from ideal bond length (A˚) 0.014 0.014 0.014





aThe inhibitor structure is shown in Figure S2.
bValues within parentheses refer to the highest resolution shell.
cResidual after TLS parameterization.
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Activation and Substrate Recognition of DYRKsremainder of the N terminus, especially for class II DYRKs, which
have NAPA1 and NAPA2 regions (Figure 3C). Although many of
the DH box interactions are conserved between DYRK1A and
DYRK2, we observed more hydrogen-bonding interactions in
the DYRK1A structure. In particular, in DYRK1A, the central tyro-
sine, Tyr147, interacts with the DYRK1A equivalent of the NAPA2
region, Glu153 and Trp155. These residues are not present in the
standard NAPA2 region of DYRK2, and DYRK2 does not have an
equivalent interaction between the DH box and NAPA2 regions
(Figure 3B). Recent evidence suggests phosphorylation of
DYRK1A at Tyr145 and Tyr147 may have important regulatory
roles (Kida et al., 2011). Tyr145 is solvent exposed, but phos-
phorylation of Tyr147 would change its interactions significantly,
although it is not possible to predict whether this would be favor-
able or unfavorable, because pTyr147 could maintain interac-
tions with Arg231 and replace the interactions of Glu153.
As well as the stabilization provided by the N-terminal region,
the 11 residues of the DH box itself interact with the loop linking
aC with b3, providing stabilization to an ‘‘aC-in’’ active kinase
conformation by fixing the N-terminal end of aC in position and
so preventing aC from moving outward, as sometimes seen inStructure 21inactive kinase structures (Figure 3A). Interestingly, the interac-
tion appears not to be charge dependent, unlike for the interac-
tion of the N-terminal hairpin of CLK3 (Bullock et al., 2009) with
the kinase N-terminal lobe (Figure S4).
The DYRK2 NAPA1 and NAPA2 regions, which are separated
in sequence, fold together into a small domain that stabilizes the
N-terminal lobe of the kinase domain (Figures 3C and 3D). The
larger NAPA1 region folds around the five residues of the
NAPA2 region. As with the DH box, the most highly conserved
residues (marked in Figure 3D) are those forming the core of
this folded subdomain, in particular His144 and Tyr147 from
NAPA2. It is notable that the residues on the end of strand b4
(DYRK2: Phe218, Phe220, Arg221), which interact with the
NAPA2 region (Figure 3D), are conserved across all human
DYRKs (Figure S1). For DYRK1A, an early folded intermediate
is implicated in enabling transient Tyr autophosphorylation in
cis (Lochhead et al., 2005). The presence of small N-terminal do-
mains (DH/NAPA1/NAPA2) capable of folding independently
and that stabilize the kinase domain may explain how during
translation a stabilized and catalytically active conformation
can be achieved before translation is complete., 986–996, June 4, 2013 ª2013 Elsevier Ltd All rights reserved 989
Figure 3. The N-Terminal NAPA and DHBox
Regions
The DH box region is in dark blue, the NAPA1 re-
gion for DYRK2 is in green, and the NAPA2 regions
for DYRK1A and DYRK2 are in cyan. Residues in
these motifs that are highly conserved across
DYRK kinases from different species (Kinstrie
et al., 2010) are labeled.
(A) DH box region of DYRK1A.
(B) DH box region of DYRK2.
(C) Overview of the N terminus of DYRK2 showing
NAPA and DH box motifs.
(D) NAPA1 and NAPA2 regions of DYRK2 showing
their folded, assembled state.
See also Figure S4.
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Activation and Substrate Recognition of DYRKsThe DYRK Activation Segment Is Stabilized by Tyr
Phosphorylation
The structures of DYRK1A and DYRK2 both show a completely
ordered activation segment in a similar conformation (Figure 2).
The second tyrosine of the YxY dual-phosphorylation motif
(DYRK1A: Tyr321; DYRK2A: Tyr309) is the main mediator of a
network of interactions that stabilize the active conformation,
including with Arg325 and Arg328 (numbering for DYRK1A)
that precede the APE motif, and with the backbone carbonyl of
the catalytically important Gln323 (Figure 4A).
Related CMGC kinases such as ERK2 have a TxY motif, and
phosphorylation of the first residue of thismotif, the threonine, al-
lows formation of salt bridges with the arginine of the usually
conserved activation segment HRDmotif, neutralizing its charge
(Canagarajah et al., 1997; Dajani et al., 2001). However, in all
DYRK kinases, the HRD arginine is replaced by a cysteine, sug-
gesting that phosphorylation of the primary phosphorylation site
is not required for activity. In both DYRKs, the HCD motif
cysteine (DYRK1A: Cys286; DYRK2: Cys274) is within range of
potential disulfide-bond formation with a cysteine at the begin-
ning of the activation loop (DYRK1A: Cys312, 4.4 A˚ distant;
DYRK2: Cys300, 4.2 A˚ distant), raising the possibility that
DYRK kinase activity might be regulated by the cellular redox
state (Figure 4A). No disulfide bonds were observed in the
crystallized proteins, which were prepared under reducing
conditions.
Comparison with the diphosphorylated ERK2 structure (PDB
ID code 2ERK) reveals only small differences in the overall acti-
vation loop conformation, mainly due to sequence and loop
length variations (Figures 4A and 4B). However, the positions
of the TxY/YxY motifs are well conserved. The primary phos-
phorylation site pT183 in ERK2 links aC (Arg68) with the activa-
tion segment and with the catalytic loop, the HRD motif. In
DYRKs, the first tyrosine residue (DYRK1A: Tyr319; DYRK2A:
Tyr307) forms a hydrogen bond with Gln199 from aC. Therefore,990 Structure 21, 986–996, June 4, 2013 ª2013 Elsevier Ltd All rights reservedthere is an interaction with aC that is inde-
pendent of phosphorylation; neverthe-
less, the direct contribution of DYRK1A
Tyr319 toward catalytic activity and tyro-
sine autophosphorylation has been found
to be negligible (Himpel et al., 2001). The
phosphate moiety of the second YxY
motif tyrosine is therefore the major acti-vation loop phosphorylation site for DYRKs; it forms similar inter-
actions as those of the secondary phosphorylation site of ERK2
at Tyr185.
DYRK1A Autophosphorylates Serine and Threonine as
Well as Tyrosine In Vitro
The intact mass spectra of purified DYRK1A and DYRK2 clearly
indicated multiple phosphorylation states. We coexpressed
DYRK1A with l-phosphatase in bacteria, yielding DYRK1A
singly phosphorylated at Tyr321. This protein was subjected to
autophosphorylation in vitro, generating up to three additional
phosphorylation sites after the reaction ran to completion, as
measured by mass spectrometry. The resulting sites were map-
ped by liquid chromatography-tandem mass spectrometry
(LC-MS/MS) (Table 2; Figure S5); sites were identified at
Tyr140 and Tyr159 in the DH box region, Tyr177 in b2 of the
N-terminal lobe, Ser310 immediately C-terminal of the DFG
motif, Tyr319 of the YxY motif, and Tyr449 located near the
C terminus of the molecule (Figure 5C). To rule out that tyrosine
autophosphorylation was due to the short construct used for
crystallization, we generated additional constructs of DYRK1A
1–485 and 37–485 and again looked for autophosphorylation
sites. LC-MS/MS confirmed Tyr autophosphorylation on
Tyr111, which was not present in the shorter constructs. The
mapped sites demonstrate the capability of DYRK1A to auto-
phosphorylate on tyrosine after the formation of mature, folded
protein in vitro, which is contradictory to previous data based
on experiments with D. melanogaster DYRKs, which reported
tyrosine phosphorylation as a one-time-only event during trans-
lation (Lochhead et al., 2005). However, these data agreewith re-
ports of weak Tyr phosphorylation observed by Adayev et al.
(2007) using a specific pTyr antibody. The distant location of
many sites from the active site also suggests that most of these
phosphorylations were carried out in trans rather than in cis.
Although all the identified phosphorylation sites are conserved
Figure 4. Activation Loop and Active State
Stabilization
Comparison of the activation segment arrange-
ments of (A) DYRK1A, activation segment in
orange, and (B) dual-phosphorylated ERK2, acti-
vation segment in green. The ERK2 structure is
from PDB ID code 2ERK. Both DYRK1A and ERK2
have a completely ordered activation loop and
glycine-rich loop, and active aC conformations.
The activation loop in dual-phosphorylated active
ERK2 forms an extensive hydrogen-bonding
network around pT183. Phosphorylated Y185 is
also stabilized through an extensive interaction
network that is similar to the pY321 network
formed by DYRK1A.
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Activation and Substrate Recognition of DYRKswithin the DYRK family and also across various species, the Tyr
phosphorylation is weak, and any physiological significance of
phosphorylation at these phosphorylation sites is yet to be es-
tablished. Interestingly, phosphorylation on Tyr145 and Tyr147
has recently been identified as a modification that determines
nuclear localization of DYRK1A in neurons (Kida et al., 2011).
To analyze the importance of Tyr321 phosphorylation for
activity, we also measured autophosphorylation kinetics for a
DYRK1A Y321F mutant. This mutant was not phosphorylated
after coexpression with l-phosphatase, but under the same
in vitro reaction conditions we observed autophosphorylation
activity (Figures 5A and 5B). To verify the activity of our DYRK1A
126–485 constructs and the suitability of the consensus peptide
used for cocrystallization (see below), we measured activity of
the 126–485wild-type and Y321Fmutant in an in vitro assay (Fig-
ure S6). Y321F had 72% of wild-type activity against the
consensus peptide, in general agreement with previous activity
measurements on other DYRK1A constructs (Himpel et al.,
2001). To assess the importance of pTyr321 for DYRK1A stabil-
ity, we measured DTm data for DYRK1A 126-485 wild-type and
Y321F; the Y321Fmutantmelted at an approximately 12C lower
temperature compared to wild-type (Figure 5D).
The Phosphorylation Substrate Recognition Motifs of
DYRKs
Initially, DYRKs were considered to be proline-directed kinases
with a similar recognition motif as ERKs. However, subsequent
biochemical studies identified substrates with a variety of recog-
nition sequences. We employed an in vitro kinase substrate
screening method using naturally occurring substrates from
HeLa cells (Kettenbach et al., 2012) to identify the substrate
recognition motifs for class I and II DYRKs, DYRK1A and
DYRK2. The results showed that DYRK1A phosphorylates sub-
strates exclusively on serine or threonine residues, on peptides
that have smaller hydrophobic residues at the P+1 position (Fig-
ure 6A). Another notable preference observed was arginine at
P2 to P4, positions poised for occupying the C lobe electro-
negative pocket. In the case of DYRK2, proline is strongly
preferred at P+1, recognizing S/TP motifs and S/TPxP motifs,
but the arginine preference at P2 to P4 is not as strong as
with DYRK1A (Figure S7). Arginine at P3 has been previously
shown to be more favorable than at P2 on a small selection
of artificial peptides with DYRK2 and DYRK3 (Campbell
and Proud, 2002). On a larger set of nonendogenous peptides,Structure 21preference for P3 arginine was shown to be a feature of
DYRK1A but not DYRK2 or DYRK4 (Papadopoulos et al., 2011).
The substrate specificities identified from HeLa cell extracts
correlate well with previous studies that have identified DYRK1A
substrates such as Tau (Ryoo et al., 2007; Liu et al., 2008), am-
phiphysin (Murakami et al., 2006), and caspase 9 (Seifert et al.,
2008) that conform to the above definition (proline at P+1 posi-
tion and arginine at P positions), whereas other studies report
substrates such as spliceosomal protein SF3b1 (de Graaf et al.,
2006) that contain proline in the P+1 position but not basophilic
residues at P positions. Furthermore, DYRK1A substrates
a-synuclein (Kim et al., 2006) and p53 (Park et al., 2010) do not
contain either of these substrate specificity determinants, indi-
cating the flexibility of DYRK1A in substrate recognition.
Ternary Complex Structure of DYRK1A Comprising
Consensus Substrate Peptide
To further explore the substrate recognition of DYRKs, we deter-
mined the crystal structure of the ternary complex of DYRK1A
with the consensus substrate peptide RARPT*PALRE and
DJM2005 (Figure 6B). Although several consensus peptides
were used in cocrystallization experiments, crystals were only
obtained with this substrate peptide. Electron density for 8 of
the 11 peptide amino acids was visible, from P4 Ala to P+3
Leu. The peptide binds in an extended conformation in the cleft
formed by the activation segment and catalytic loop. There were
no major protein conformational changes upon peptide binding.
The hydroxyl group of the P0 threonine forms hydrogen bonds
with the catalytic loop aspartate (Asp287) and the highly
conserved Lys289 of the catalytic loop flanking region and
Ser324 of the activation loop (Figure 6D). The P+2 leucine and
P+3 alanine bind against a hydrophobic pocket formed by
Phe196 from aC and Phe170 from the glycine-rich loop, explain-
ing the preference for hydrophobic residues at these substrate
positions. The P+1 proline was bound adjacent to the catalyti-
cally important Gln323 (Wiechmann et al., 2003) and also against
the aromatic ring of pTyr321 (Figure 6E). The small size and lack
of charge in this pocket explains why only substrates with small
aliphatic residues at P+1were acceptable. The P3 arginine was
bound in a negatively charged pocket formed byGlu291, Tyr327,
Tyr246, and Glu353 (Figures 6E and 6F). Interestingly, it faces to-
ward the activation segment in the C lobe, not the glycine-rich
loop, but stabilizes the aD helix through the interactions with
Tyr246 on aD. However, the binding pocket is extended and, 986–996, June 4, 2013 ª2013 Elsevier Ltd All rights reserved 991













Related to Figure S5.
aOnly observed for DYRK1A 1–485 or 37–485, not for DYRK1A 127–485.
Structure
Activation and Substrate Recognition of DYRKsso it may also accommodate substrate arginines located in the
2 and 4 positions, again fitting with the observed DYRK1A
substrate profile.
DISCUSSION
It has been established that DYRKs autoactivate shortly after
translation through autophosphorylation of the YxpY motif of
the activation segment (Becker et al., 1998; Becker and Joost,
1999; Lochhead et al., 2005). The DYRK structures revealed
that phosphorylation of Tyr321 stabilizes the activation segment
in a similar way to that observed for phosphorylated ERK2 (Can-
agarajah et al., 1997). The rapid autoactivation of DYRK kinases
immediately after translation raises the question of how DYRK
activity is regulated. Mouse models and truncations of DYRK1A
in patients with microcephaly demonstrated that deregulation of
DYRK1A activity has severe phenotypic consequences (Fotaki
et al., 2002;Møller et al., 2008). Several reports point to transcrip-
tional regulation, and the presence of PEST sequences (Figure 1)
suggests a quick turnover (Maenz et al., 2008; Arron et al., 2006).
The current model suggests that Tyr321 phosphorylation is a
‘‘one-time-only’’ event that happens during maturation of
DYRK1A while bound to the ribosome. For class II DYRKs
(DYRK2, 3, and 4), this process requires the N-terminal NAPA
regions, which are absent/modified in class I DYRKs (DYRK1A
and 1B). The DYRK2 structure shows how the DH box and
NAPA regions bind across the N-terminal lobe of the kinase
domain, via significant conserved interactions at the kinase
domain loops between b3 and aC and between b4 and b5.
Thus, the DH box and NAPA regions come together to form a
domain that can fold before translation of the kinase domain is
complete and assist in the folding of the kinase domain. Presum-
ably, this enables a partially folded intermediate with the previ-
ously observed transient tyrosine kinase capability.
However, our data, with human enzymes as opposed to the
D. melanogaster enzymes used previously (Lochhead et al.,
2005), also showed that tyrosine autophosphorylation can occur
weakly in vitro and is not restricted to the Tyr321 site (DYRK1A)
and that this activity is independent of Tyr321 phosphorylation,
although a possible caveat is that the constructs used were
the same as those used for crystallization, and not the full-length992 Structure 21, 986–996, June 4, 2013 ª2013 Elsevier Ltd All rightsprotein. In vitro autophosphorylation at Tyr111 has been re-
ported previously (Himpel et al., 2001), but mutation of this res-
idue was shown to have no influence on catalytic activity.
Tyr111 is located N-terminal to the DH box and was not included
in the construct used for the crystal structure. The importance of
phosphorylation of Tyr321 and Tyr319 for activity has been re-
ported by several groups (Himpel et al., 2001; Lochhead et al.,
2005). These studies showed that Tyr321 is the main phosphor-
ylation site observed in recombinant protein expressed in both
bacteria and eukaryotic cells. Mutation Y321F dramatically re-
duces catalytic activity, whereas Y319F does not alter activity
(Adayev et al., 2007; Wiechmann et al., 2003). Some other muta-
tions (e.g., double mutants Y319Q/Y321Q and Y319H/Y321H)
also retain considerable activity (Adayev et al., 2007). The
DYRK1A structure provides explanations for these observations,
as the mutations to polar side chains would still allow the activa-
tion segment to retain favorable polar interactions with residues
that coordinate pTyr321 (Arg325, Arg328, Glu366). By analogy,
the activity of nonphosphorylated Tyr321 (Adayev et al., 2007)
is also explained by the continued ability of Tyr321 to retain
some favorable polar interactions that would stabilize an active
conformation of the activation loop.
Substrate peptide profiling did not reveal any tyrosine phos-
phorylation, suggesting that tyrosine kinase activity is limited to
autophosphorylation events. Comparison of the DYRK1A sub-
strate complex with substrate-bound tyrosine kinase structures
shows little similarity, and the substrate binding site in DYRK1A
has the typical appearance of those in S/T kinases. Kinase auto-
phosphorylation has been shown to frequently target noncon-
sensus sequences (Pike et al., 2008; Oliver et al., 2007). More-
over, our data revealed that DYRK1A S/T phosphorylation
activity is not stringently proline directed and that substrates
with small hydrophobic residues such as valine or alanine in
the P+1 position can be recognized.
Finally, as well as explaining the observed substrate specific-
ities, the presented structures will serve as amodel for the devel-
opment of more potent and selective ligands that might find
application in the treatment of neurodegenerative diseases.EXPERIMENTAL PROCEDURES
Cloning
DNA for DYRK1A residues 127–485 (NCBI gi number 18765758) or DYRK2A
residues 74–479 (NCBI gi number 4503427) was PCR amplified and subcloned
into a pET-based vector carrying kanamycin resistance, pNIC28-Bsa4 (Gen-
Bank accession number EF198106), using ligation-independent cloning. The
resulting plasmids expressed the kinase domains of DYRK1A or DYRK2,
with an N-terminal hexahistidine tag and tobacco etch virus protease tag
cleavage site (extension MHHHHHHSSGVDLGTENLYFQ*SM-). DYRK1A
1–485 and 37–485 constructs were generated similarly. DYRK1A 127–485
Y321F and K188R mutants were generated by the overlapping PCR product
method.
Expression and Purification
Constructs were used to express protein in Escherichia coli BL21 (DE3) cells,
and protein was purified using standard methods (see Supplemental Experi-
mental Procedures).
Crystallization and Data Collection
All crystals were obtained using the sitting-drop vapor-diffusion method
at 4C. Data collection statistics and crystallization conditions can bereserved
Figure 5. Phosphomapping and Autophos-
phorylation
(A) Autophosphorylation kinetics of DYRK1A
Y321F showing electrospray ionization-MS
spectra recorded after 0 hr, 4 hr, and overnight.
(B) Phosphorylation capability of DYRK1A Y321F
mutant. The top panel shows a western blot of
DYRK1A Y321F autophosphorylation probed by
anti-phosphotyrosine antibody after the reaction
times indicated. The bottom panel shows a quan-
titative control with equal amounts of sample run
on the gel. Related to Figure S6.
(C) The autophosphorylation sites mapped for
wild-type DYRK1A are shown on the structure as
green sticks.
(D) Thermal unfolding of DYRK1A wild-type and
Y321F mutant.
See also Figure S6.
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Activation and Substrate Recognition of DYRKsfound in Table 1. More detail is available in Supplemental Experimental
Procedures.
Structure Determination
All diffraction data were indexed and integrated using MOSFLM (Leslie and
Powell, 2007) and scaled using SCALA (Evans, 2006). All models were refined
with REFMAC5 (Murshudov et al., 2011).
The DYRK1A structure was solved by molecular replacement using Phaser
(McCoy et al., 2007) and a search ensemble of the coordinates from two CLK
kinases (PDB ID codes 2EXE and 1Z57). Four molecules were present in the
asymmetric unit and, after NCS averaging and density modification in dm
(Cowtan, 1994), the resulting phases could be utilized in ARP/wARP (Langer
et al., 2008) to autobuild the main parts of one of the molecules in the asym-
metric unit. After further model building in Coot (Emsley et al., 2010), this mole-
cule was used to generate the other three molecules for restrained refinement
with tight NCS restraints. Rebuilding and refinement (including TLS parame-
ters) resulted in the final model.
The DYRK1A peptide complex and the DYRK2 structure were both solved
by molecular replacement using Phaser, with the structure of the inhibitor-
bound DYRK1A as a search molecule.
Analysis of DTm upon Inhibitor Binding
Changes in Tm caused by small-molecule binding were correlated for 433
compounds that caused an increase in Tm of >2
C for either DYRK1A or
DYRK2 and for which a measurement was available for both proteins. The
measurements were made according to established protocols (Niesen et al.,
2007).
Autophosphorylation
DYRK1A proteins weremixedwith ATP (1mM) andMg2+ (2mM) and incubated
at room temperature. Western blot analysis of phosphotyrosine was per-
formed using rabbit anti-pTyr antibody (Cell Signaling Technology).
In-Solution Digestion
The DYRK1A protein from in vitro autophosphorylation was diluted in 100 ml of
an 8 M urea buffer (6 M urea, 2 M thiourea in 10 mM HEPES [pH 8]). The pro-
tein was reduced for 30 min at room temperature with 1 mM dithiothreitol and
then alkylated for 15 min by 5.5 mM iodoacetamide. Endoproteinase Lys-CStructure 21, 986–996, June 4, 2013(Wako) was added 1:100 (w/w) and the lysates
were digested for 4 hr at room temperature. The
resulting peptide mixtures were diluted 4-fold
with deionized water to achieve a final urea
concentration below 2 M. Trypsin (modified
sequencing grade; Promega) was added 1:100
(w/w) and the sample was digested overnight.
Trypsin and Lys-C activity was quenched by acid-ification of the reaction mixtures with a 10% TFA solution to pH 2. The
peptide mixture was desalted and concentrated on a reverse-phase C18
StageTip (Rappsilber et al., 2007) and eluted with 23 20 ml of 60% acetonitrile
in 0.3% TFA.
In-Gel Digestion
The excised gel plugs with the DYRK1A protein were digested in situ with
trypsin as previously described (Shevchenko et al., 2006).
Phosphopeptide Enrichment and Analysis
Phosphopeptides were enriched using titansphere chromatography as
described previously (Olsen et al., 2006), and analyzed by online nanoflow
LC-MS/MS as described previously (Olsen et al., 2006) with a few
modifications. More detail is available in Supplemental Experimental
Procedures.
Kinase Assays
Peptide substrates were chemically synthesized by Thermo Peptides or
Generon. The phosphorylation reactions were measured using a spec-
trophotometric assay (Adams et al., 1995) in which ADP production is
coupled to NADH oxidation by pyruvate kinase and lactate dehydroge-
nase (LDH). The reaction was followed by the decrease in NADH
fluorescence (excitation 350 nm, emission 460 nm). The assay mixture
contained 30 U/ml LDH, 12 U/ml pyruvate kinase, 1 mM phosphoenol-
pyruvate, 0.2 mM NADH, 25 mM HEPES (pH 7.5), 150 mM NaCl, 5 mM
MgCl2, and DYRK1A (wild-type or mutants). The concentration of the
consensus substrate peptide (RARPGTPALRE) was 0.25 mM. After
incubation for 1–5 min, the reaction was initiated by the simultaneous
addition of 1 mM ATP. The initial reaction rate was used to compare
activities of wild-type and mutants. Control reactions in the absence of
substrate were used to detect ATPase activity for basal correction. A
K188R mutant was also measured to control for any peptide-stimulated
ATPase activity.
Determination of Peptide Phosphorylation Specificity
Peptides derived from HeLa cell-lysate digests that were phosphorylated
by DYRKs were identified as in published procedures (Kettenbach et al.,
2012).ª2013 Elsevier Ltd All rights reserved 993
Figure 6. Substrate Binding of DYRK1A
(A) Representative panels of DYRK1A substrate specificity defining peptide residues identified using in vivo isolation. Each panel represents a separate clustering
of peptide sequences, with themost commonly observed residues at each position at the top of each letter stack. Within each clustering, the fraction of the height
occupied by each residue represents its predominance at that position.
(B) Ternary complex of DYRK1A substrate peptide and inhibitor DJM2005 bound to DYRK1A. The substrate peptide is shown bound between the two lobes of the
kinase in the binding cleft extending from the ATP site toward helix aC. The DH box and kinase domain of DYRK1A are shown as an electrostatic surface
representation, with the substrate peptide in white balls and sticks and residues of substrates labeled with reference to the phosphoacceptor residue (threonine
T0).
(C) Electron density map of the DYRK1A substrate peptide for the 8 out of 11 residues for which the density was visible in the structure, numbered with respect to
phosphoacceptor threonine T0.
(D) Close-up view of the atomic arrangement around the phosphoacceptor residue threonine T0.
(E) Close-up view of the arginine binding pocket of DYRK1A, where the arginine at position3 of the substrate binds to negatively charged residues of the C lobe
(red-colored surface) and forms an extensive bonding network with residues from the activation loop, aD and aF.
(F) Stick representation similar to (E).
See also Figure S7.
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